Race Oncology Shares Go Up On Zantrene Improvements
Wednesday morning saw healthcare stock Race Oncology [ASX:RAC], developer of cancer drug treatments and melanoma therapies, provide an update on an improved formulation of its Zantrene (RC220) product.





